"The voice for cancer physicians and their patients in Massachusetts."

Updates Healthcare Common Procedure Coding System Code (HCPCS) and dose descriptor for Amgen's Neulasta® (pegfilgrastim) Onpro® and Neulasta®

08 Dec 2021 7:30 AM | Katy Monaco (Administrator)

Neulasta® (pegfilgrastim) Onpro® and Neulasta® have an updated Healthcare Common Procedure Coding System (HCPCS) Code and dose descriptor, effective January 1, 2022.

The UPDATED HCPCS CODE is J2506.  The UPDATED DOSE DESCRIPTOR is Injection, pegfilgrastim, excludes biosimilar, 0.5 mg.  This updated dose descriptor can be billed in multiple units to accommodate a variety of doses. Providers should note the new dose descriptor is now 0.5 mg. Per label, the dose for Neulasta® (pegfilgrastim) is 6 mg. Please accurately report service units when billing.

Key dates: For dates of service on and after January 1, 2022, providers must use the updated HCPCS Code J2506, and dose descriptor, and discontinue use of the HCPCS Code J2505, as it will no longer be accepted. Providers may only use J2505 for dates of service on or before December 31, 2021.

Information on the updated code and dose descriptor is summarized in the following attachments:

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software